¿Cómo se comparó el EPS reciente de CMPS con las expectativas?
¿Cómo fue el desempeño de los ingresos de Compass Pathways PLC CMPS en el último trimestre?
¿Cuál es la estimación de ingresos para Compass Pathways PLC?
¿Cuál es la puntuación de calidad de ganancias de Compass Pathways PLC?
¿Cuándo informa Compass Pathways PLC sus ganancias?
¿Cuáles son las ganancias esperadas de Compass Pathways PLC?
¿Superó Compass Pathways PLC las expectativas de ganancias?
Estadísticas clave
Cierre Anterior
$7.31
Precio de apertura
$7.31
Rango del día
$7.1 - $7.47
Rango de 52 semanas
$2.25 - $7.35
Volumen
748.7K
Volumen promedio
1.6M
EPS (TTM)
-2.68
Rendimiento de dividendos
--
Cap. de mercado
$687.6M
¿Qué es CMPS?
Compass Pathways Plc is a biotechnology company, which provides mental health care services. The company is headquartered in Altrincham, Cheshire and currently employs 166 full-time employees. The company went IPO on 2020-09-18. The firm is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. The company commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. The company also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.